

25.07.2019

BSE Limited  
Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building,  
Phirozejeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,  
Department of Corporate Services,  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051.  
Scrip Code : CAPLIPOINT

By NEAPS

Dear Sirs,

**SUB: PRESS RELEASE- DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015**

Please find the enclosed copy of Press Release being published today.

Thanking you,

Yours Faithfully,  
For **CAPLIN POINT LABORATORIES LIMITED**



**COMPANY SECRETARY**  
Enclosure : As above



## PRESS RELEASE

### **CAPLIN RECEIVES ESTABLISHMENT INSPECTION REPORT FOR INJECTABLE FACILITY.**

**Chennai, July 25, 2019:** Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited, is pleased to announce that it has received the Establishment Inspection Report (EIR) from US FDA for the recently concluded inspection in June 2019.

This was the third successful US FDA audit at the plant since 2016. Mr C.C.Paarthipan, Chairman of Caplin Point Laboratories Limited commented "We're glad to receive the EIR within a short period of completing the inspection. Our commitment to maintaining the highest quality standards remain strong. We're also starting to see traction in terms of product approvals and commercial batches being rolled out of this facility."

### **ABOUT CAPLIN POINT LABORATORIES LTD**

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Wholly Owned Subsidiary Caplin Steriles Limited,

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

### **CAUTIONARY STATEMENT:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*





For details, please contact:

**Investor Relations Team at Caplin**

Mr.Vinod Kumar (Company Secretary)

**Tel: +91 44 24968000**

[investor@caplinpoint.net](mailto:investor@caplinpoint.net)

**Dikshita Jain**

Christensen Investor Relations

Tel : +91 22 4215 0210

[djain@christensenir.com](mailto:djain@christensenir.com)

**Registered Office**

Narbhavi No. 3, Lakshmanan Street,

T Nagar, Chennai, Tamil Nadu, 600017

Telephone: 044-28156653

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: [www.caplinpoint.net](http://www.caplinpoint.net)

